IUPAC/Chemical Name
(4aS,6aR,6bR,8aR,12aR,12bR,14bS)-6a-(hydroxymethyl)-2,2,6b,9,9,12a-hexamethyl-10-oxo-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylic acid
InChi Key
WVGVTIMZQLYBLX-SXOOSYOQSA-N
InChi Code
1S/C30H46O4/c1-25(2)13-14-29(24(33)34)15-16-30(18-31)19(20(29)17-25)7-8-22-27(5)11-10-23(32)26(3,4)21(27)9-12-28(22,30)6/h7,20-22,31H,8-18H2,1-6H3,(H,33,34)/t20-,21-,22+,27-,28+,29-,30-/m0/s1
SMILES Code
[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]3(CO)C2=CC[C@]4([H])[C@@]5(C)CCC(=O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
470.69
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Maguire JJ, Bacon CR, Fujimoto M, Davenport AP. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994 Jun;12(6):675-80. PMID: 7963492.
2: Singh V, Mujwar S, Singh M, Singh T, Ahmad SF. Computational Studies to Understand the Neuroprotective Mechanism of Action Basil Compounds. Molecules. 2023 Oct 10;28(20):7005. doi: 10.3390/molecules28207005. PMID: 37894484; PMCID: PMC10609097.
3: Mihara S, Nakajima S, Matumura S, Kohnoike T, Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. J Pharmacol Exp Ther. 1994 Mar;268(3):1122-8. PMID: 8138925.
4: Iwasaki T, Hayasaki-Kajiwara Y, Shimamura T, Naya N, Nakajima M. Endothelin receptor subtype antagonist activity of S-0139 in various isolated rabbit and canine arteries. Eur J Pharmacol. 2000 Jul 21;400(2-3):255-62. doi: 10.1016/s0014-2999(00)00417-9. PMID: 10988342.
5: Mihara S, Sakurai K, Nakamura M, Konoike T, Fujimoto M. Structure-activity relationships of an endothelin ETA receptor antagonist, 50-235, and its derivatives. Eur J Pharmacol. 1993 Oct 15;247(2):219-21. doi: 10.1016/0922-4106(93)90081-j. PMID: 8282010.
6: Mihara S, Tozawa F, Itazaki K, Fujimoto M. Binding characterization of [3H]S-0139, an antagonist of the endothelin ET(A) receptor subtype. Eur J Pharmacol. 1998 Jan 26;342(2-3):319-24. doi: 10.1016/s0014-2999(97)01479-9. PMID: 9548403.
7: Mihara S, Fujimoto M. The endothelin ETA receptor-specific effect of 50-235, a nonpeptide endothelin antagonist. Eur J Pharmacol. 1993 Jun 15;246(1):33-8. doi: 10.1016/0922-4106(93)90006-u. PMID: 8354341.
